Investor Area

Analyst Coverage

CUV announced that it has submitted a marketing authorisation application (MAA) for its drug afamelanotide (16mg implant) to the European Medicines Agency (EMA). The MAA covers the use of afamelanotide as a prophylactic treatment in adult patients with erythropoietic protoporphyria (EPP), a rare disease which causes absolute intolerance of patients’ skin to light. Approval...
Download PDF
 
Wednesday, 04 January 2012

Edison QuickView: Positive in Phase III

Positive results in the second Phase III study of CLINUVEL’s Scenesse (afamelanotide), a photoprotective drug for treating the orphan condition erythropoietic protoporphyria (EPP), put the drug on track for an EU approval filing, due shortly, and could be a contributory factor in the FDA’s decision to conduct a Phase III trial.
Download PDF
 
The latest analyst coverage of CLINUVEL from Nomura has just been released. To view this, click here: CUV announces positive results from pivotal European Phase III study.
Download PDF
 
CLINUVEL demonstrates positive treatment effect of afamelanotide in US Phase II study Analyses from US confirmatory study demonstrated a dramatic improvement in Quality of Life from afamelanotide 16mg in the orphan disease erythropoietic protoporphyria (EPP).
Download PDF
 
Considerable upside from potentially successful NSV trials
Download PDF
 
We believe the Vitiligo market is currently underserved.
Download PDF
 
CLINUVEL (CUV) posted 1H FY11 results above our forecasts.
Download PDF
 
Tuesday, 30 November 2010

NOMURA Analyst Report

Updating for share consolidation
Download PDF
 
Wednesday, 25 August 2010

NOMURA Analyst Report

Expanding addressable market
Download PDF
 
Independent research by Reuters – Buy Recommendation
Download PDF
 
In our view, CUV is moving ever closer to final approval of its drug, afamelanotide.
Download PDF
 
RBS Update “Interim Phase III results revealed”
Download PDF
 
Thursday, 17 December 2009

RBS Update

 
Friday, 11 December 2009

RBS – Health Care sector update

RBS – Health Care sector update
Download PDF
 
RBS Update: CLINUVEL Continues to confirm potential
Download PDF